Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
NCT Number: NCT00320619
Individuals who undergo spine surgery often have a significant loss of blood and may require multiple blood transfusions. Research has shown that epsilon-aminocaproic acid (EACA) may reduce the amount of blood lost during surgery, which would decrease the number of blood transfusions required. This study will evaluate the safety and effectiveness of EACA at reducing blood loss and the need for blood transfusions in individuals undergoing spine surgery.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Baltimore, Maryland, 21287, United States
Spine surgery is often required to correct a number of diseases, including spondylosis, pseudoarthrosis, scoliosis, or other spinal deformities. Spine surgery is often associated with significant blood loss and individuals may require multiple blood transfusions during and following surgery. Blood transfusions are expensive and carry an increased risk of health complications, including fever, allergic reactions, or infections. Preliminary research has shown that EACA may be beneficial for individuals undergoing spine surgery. In addition, EACA appears to be safer and less expensive than other medications typically used to treat serious bleeding. The purpose of this study is to evaluate the safety and effectiveness of EACA at reducing the number of blood transfusions required during and following spine surgery in adults.
This study will enroll individuals who are undergoing spine surgery at Johns Hopkins Hospital. Prior to surgery, participants' demographic data and medical history will be collected. Participants will then be randomly assigned to receive either EACA or placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU). While in the hospital, participants will have blood drawn frequently for laboratory testing. They will receive blood transfusions as needed and will be closely monitored for blood loss and any medical, surgical, or transfusion complications. Outcome measurements related to the amount of transfused blood required and postoperative complications will be collected on the 8th day following surgery. Study participation will end on the day of hospital discharge or the day of a necessary second surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
Time frame: Measured through the 8th postoperative day
Time frame: Measured through the 8th postoperative day
Time frame: Measured through the 8th postoperative day
Time frame: Measured through the 8th postoperative day
Time frame: Measured through the 8th postoperative day
Time frame: Measured through the 8th postoperative day
Time frame: Measured through the 8th postoperative day
Time frame: Measured through the 8th postoperative day
Time frame: Measured through the 8th postoperative day
Time frame: Measured through the 8th postoperative day
Time frame: Measured through the 8th postoperative day
National Heart, Lung, and Blood Institute (NHLBI)
Nih
Aminocaproic Acid and Bleeding in Spinal Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06532968
Back Injuries, Bone Diseases
Taipei, Taiwan
View Trial DetailsNCT01588054
Bone Diseases, Cervical Deformity
La Jolla, California, United States
View Trial DetailsNCT02994030
Atrophy, Bacterial Infections
Tirana, Albania
View Trial DetailsNCT00890227
Bone Diseases, Kyphosis
Baltimore, Maryland, United States
View Trial Details